Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. develops precision therapies for solid tumors designed to preserve organ function. The clinical-stage biotechnology company’s recurring updates center on bel-sar (AU-011), its lead candidate in late-stage development for early choroidal melanoma and in early-stage development for other ocular oncology indications and bladder cancer.
Company news also covers financial results, clinical-program business highlights, investor conference participation, executive leadership changes, and capital actions involving common stock and pre-funded warrants. Aura’s disclosures frequently connect pipeline progress with oncology indications, trial activity, liquidity planning, and governance developments.
Aura Biosciences, a clinical-stage oncology firm, has priced its initial public offering (IPO) at $14.00 per share for 5,400,000 shares, aiming to raise approximately $75.6 million. The offering is scheduled to begin trading on the Nasdaq Global Market under the ticker AURA on October 29, 2021, with the closing date set for November 2, 2021. Aura has also granted underwriters a 30-day option for an additional 810,000 shares. The funds will support the development of its innovative virus-like drug conjugate therapies for various cancer indications.